Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. New Zealand
  4. New Zealand Stock Exchange
  5. TruScreen Group Limited
  6. News
  7. Summary
    TRU   NZTRUE0001S7

TRUSCREEN GROUP LIMITED

(TRU)
  Report
End-of-day quote. End-of-day quote New Zealand Stock Exchange - 07/28
0.063 NZD   +1.61%
07/08TRUSCREEN : Director Nominations Closing Date
PU
07/01TRUSCREEN : First Sales Made in Eastern Europe
PU
06/30TRUSCREEN : to Ship Cervical Cancer Screening Devices to Serbia in July
MT
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TruScreen : Sichuan Province Trial Confirms Truscreen Technology

10/20/2020 | 10:25pm EDT
Truscreen Group Limited (NZX:TRU) (Truscreen or Company) is pleased to advise results from The China Obstetrics and Gynaecology Association (COGA) ongoing national clinical trial that will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China. The COGA evaluation compares the TruScreen technology to Liquid Based Cytology (LBC), and HPV DNA testing (HPV) and targets a nationwide consensus on Truscreen technology application in China as the main outcome of this large-scale trial.The outstanding initial results were previously released in an NZX announcement dated 2 September 2019 from the screening of 2,065 women across 7 hospitals in Hunan Province, China.

This second preliminary trial results were presented by the lead investigator of the COGA project in Sichuan Province at COGA's annual congress in September 2020. The trial covered 14 hospitals and 1,243 patients in the data analysis.
Truscreen's results from this second phase, outlined below, were better or on parity than tests for HPV (Human Papillomavirus DNA Test) and LBC (Liquid-cased Cytology). These results confirm Hunan Province results announced in 2019.

Truscreen had a Sensitivity of 86% (HPV 94%, LBC 73%) Specificity of 74% (HPV 18%, LBC 53%) PPV 52% (HPV 27%, LBC 34%) and NPV 94% (HPV 89%, LBC 86%).

Formal Publication will occur when the full 20,000 patients have been screened. Interim results from the Sichuan and Hunan clinical evaluation validate the strong potential for the TruScreen cervical cancer screening device to improve women's health in China.

TruScreen Chief Executive Victoria Potarina said: 'We are pleased that the Sichuan Province trial results continued to corroborate the strong results from the first completed Hunan Province trial for the COGA evaluation. These outstanding in-country trial results will reinforce to hospitals and key opinion leaders of the accuracy and ease of use of our real time Truscreen cervical screening devices.'

ENDS

TRU - SICHUAN PROVINCE TRIAL CONFIRMS TRUSCREEN TECHNOLOGY

Sensitivity measures correctly a positive result for patients who have the condition that is being tested for (also known as the 'true positive' rate). A test that's highly sensitive will indicate patients who have the disease.

Specificity measures correctly a negative result for people who don't have the condition that is' being tested for (also known as the 'true negative' rate). A high-specificity test will correctly rule out patients who do not have the disease.

PPV - Positive Predictive Value is the probability that subjects with a positive screening test truly have the disease.

NPV - Negative Predictive Value is the probability that subjects with a negative screening test truly don't have the disease.

Disclaimer

TruScreen Limited published this content on 19 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2020 02:24:02 UTC


ę Publicnow 2020
All news about TRUSCREEN GROUP LIMITED
07/08TRUSCREEN : Director Nominations Closing Date
PU
07/01TRUSCREEN : First Sales Made in Eastern Europe
PU
06/30TRUSCREEN : to Ship Cervical Cancer Screening Devices to Serbia in July
MT
06/01TRUSCREEN : FY21 Preliminary Results
PU
03/24TRUSCREEN : Research Confirms TruSreeen Suitability in COVID-19 Environment
PU
03/23TRUSCREEN : Cervical Cancer Screening Device Suitable for COVID-19 Environment
MT
03/01TRUSCREEN : Board Appointment
PU
03/01TruScreen Group Limited Announces Board Changes
CI
02/25TRUSCREEN : Executive Leadership Change
PU
02/25TruScreen Group Limited Announces Executive Changes
CI
More news
Financials
Sales 2021 1,97 M 1,37 M 1,37 M
Net income 2021 -3,49 M -2,42 M -2,42 M
Net cash 2021 5,26 M 3,64 M 3,64 M
P/E ratio 2021 -9,18x
Yield 2021 -
Capitalization 22,9 M 15,8 M 15,8 M
EV / Sales 2020 6,02x
EV / Sales 2021 15,5x
Nbr of Employees -
Free-Float 69,8%
Chart TRUSCREEN GROUP LIMITED
Duration : Period :
TruScreen Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Last Close Price 0,06 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Juliet Hull Chief Executive Officer & Director
Guy Robertson Chief Financial Officer & Secretary
Peng Ho Non-Executive Chairman
Edmond Capcelea Chief Technology Officer
Nicole Melia Manager-Administration & Marketing
Sector and Competitors